石药集团：2025 年指引在疲软第二季度后重新校准；重申业务开发目标及可持续性

August 22, 2025 12:16 PM GMT CSPC Pharmaceutical Group | Asia Pacific 2025 Guidance Recalibrated after Soft 2Q; BD Targets and Sustainability Reiterated Key Takeaways Target 5% HoH growth in 2H25 and double-digit (%) growth from 202e:6: Mingfule is on track to hit Rmb1bn in sales in 2025. NBP soft capsule sales were hurt by tightened hospital budget control in 1H. CSPC plans to strengthen its out-of- pocket retail channel to sustain Rmb2bn sales after patent expiry. EGFR ADC updates ( Exhibit 1 ): Global Ph ...